CRISPR/Cas9 in Antibody Engineering: Advances in Cell Line Optimization and Therapeutic Applications

Qianyu Zhou

doi:10.54097/6hzmgm61

Authors

Qianyu Zhou

DOI:

https://doi.org/10.54097/6hzmgm61

Keywords:

CRISPR/Cas9, Gene-editing, Antibody engineering.

Abstract

Derived from the adaptive immune system of prokaryotes, CRISPR-Cas9 gene editing technology has revolutionized biotechnology with its simplicity, efficiency and precision, and plays a crucial role in advancing biopharmaceuticals. This paper focuses on the application of the CRISPR/Cas9 in antibody engineering, especially its role in optimizing the CHO cell lines and advancing immunotherapy. The results of this paper show that in the CHO cell line optimization, CRISPR improves antibody yield by knocking down apoptotic genes (e.g., Bak1, Bax), modifies glycosylation patterns by editing FUT8 to improve antibody efficacy and safety, and reduces residual host cell proteins by double knockdown of C1s/MGAT1. In immunotherapy, CRISPR-modified CAR-T cells improved editing efficiency, minimized off-target effects, and mitigated GVHD and immune rejection through multi-gene editing. These findings highlight the dual value of the CRISPR in improving antibody production efficiency/quality and driving innovation in immunotherapy, laying the foundation for advances in biopharmaceuticals and personalized medicine.

Downloads

Download data is not yet available.

References

[1] Li, L. (2024). Preparation of Chinese hamster ovarian cell culture supernatant protein and antibody expansion library [Master's thesis, Nanchang University].CNKI.

[2] Sharma et al. (2021). CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases. Molecular therapy : the journal of the American Society of Gene Therapy, 29(2), 571–586. DOI: https://doi.org/10.1016/j.ymthe.2020.09.028

[3] Gaj et al. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology, 31(7), 397–405. DOI: https://doi.org/10.1016/j.tibtech.2013.04.004

[4] Hryhorowicz et al. (2017). CRISPR/Cas9 Immune System as a Tool for Genome Engineering. Archivum immunologiae et therapiae experimentalis, 65(3), 233–240. DOI: https://doi.org/10.1007/s00005-016-0427-5

[5] Lino et al. (2018). Delivering CRISPR: a review of the challenges and approaches. Drug delivery, 25(1), 1234–1257. DOI: https://doi.org/10.1080/10717544.2018.1474964

[6] Chen, J., Doudna, J. The chemistry of Cas9 and its CRISPR colleagues. Nat Rev Chem 1, 0078 (2017). DOI: https://doi.org/10.1038/s41570-017-0078

[7] Orlova et al. (2022). Targeted Knockout of the dhfr, glul, bak1, and bax Genes by the Multiplex Genome Editing in CHO Cells. Doklady. Biochemistry and biophysics, 502(1), 40–44. DOI: https://doi.org/10.1134/S1607672922010082

[8] Yang et al. (2021). Glycoproteomic Characterization of FUT8 Knock-Out CHO Cells Reveals Roles of FUT8 in the Glycosylation. Frontiers in chemistry, 9, 755238. DOI: https://doi.org/10.3389/fchem.2021.755238

[9] Sun et al. (2015). Functional knockout of FUT8 in Chinese hamster ovary cells using CRISPR/Cas9 to produce a defucosylated antibody. Engineering in Life Sciences, 15(6), 660–666. DOI: https://doi.org/10.1002/elsc.201400218

[10] Glinšek, K., Bozovičar, K., & Bratkovič, T. (2023). CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering. International journal of molecular sciences, 24(9), 8144. https://doi.org/10.3390/ijms24098144 DOI: https://doi.org/10.3390/ijms24098144

[11] Song et al. (2024). CRISPR/Cas-based CAR-T cells: production and application. Biomarker research, 12(1), 54. DOI: https://doi.org/10.1186/s40364-024-00602-z

[12] Hendel et al. (2015). Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nature biotechnology, 33(9), 985–989. DOI: https://doi.org/10.1038/nbt.3290

[13] Katti et al. (2022). CRISPR in cancer biology and therapy. Nature reviews. Cancer, 22(5), 259–279. DOI: https://doi.org/10.1038/s41568-022-00441-w

[14] Raghavan et al. (2025). Rational engineering of minimally immunogenic nucleases for gene therapy. Nature communications, 16(1), 105. DOI: https://doi.org/10.1038/s41467-024-55522-1

[15] Manghwar et al. (2020). CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 7(6), 1902312.

[16] Manghwar et al. (2020). CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 7(6), 1902312. DOI: https://doi.org/10.1002/advs.201902312